Literature DB >> 10522685

Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor.

J E Vaquerano, P Cadbury, P Treseler, R Sagebiel, S P Leong.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522685     DOI: 10.1001/archderm.135.10.1276

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  2 in total

1.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.

Authors:  P Radny; U M Caroli; J Bauer; T Paul; C Schlegel; T K Eigentler; B Weide; M Schwarz; C Garbe
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

Review 2.  Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.

Authors:  Howard L Kaufman; Carl E Ruby; Tasha Hughes; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2014-05-13       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.